Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer

Oncologist

Volumn 7, Issue SUPPL. 5, 2002, Pages 29-35

  Morris, Robert ^a   Munkarah, Adnan ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Infusion; Intravenous; Ovarian neoplasms; Recurrence; Topotecan

Indexed keywords

CARBOPLATIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; PACLITAXEL; TOPOTECAN;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; LETHARGY; MAXIMUM TOLERATED DOSE; NEUTROPENIA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EID: 0036387968     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-suppl_5-29     Document Type: Review

References (29)

1. Kingsbury WD, Boehm JC, Jakas DR et al. Synthesis of watersoluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 1991;34:98-107.
2. Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 1994;37:40-46.
3. Verweij J, Lund B, Beijnen J et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 1993;4:673-678.
4. Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997;8:837-855.
5. McGuire WP, Blessing JA, Bookman MA et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2000;18:1062-1067.
6. Bookman MA, Malmström H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998;16:3345-3352.
7. Creemers GJ, Bolis G, Gore M et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996;14:3056-3061.
8. ten Bokkel Huinink W, Gore M, Bolis G et al. A phase II trial of topotecan for the treatment of relapsed advanced ovarian carcinoma. Proc Am Soc Clin Oncol 1996;15:284.
9. Kudelka AP, Tresukosol D, Edwards CL et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996;14:1552-1557.
10. Swisher EM, Mutch DG, Rader JS et al. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997;66:480-486.
11. Hoskins P, Eisenhauer E, Beare S et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998;16:2233-2237.
12. Herzog TJ Update on the role of topotecan in the treatment of recurrent ovarian cancer. The Oncologist 2002;7(suppl 5):3-10.
13. Dunton CJ. Management of treatment-related toxicity in advanced ovarian cancer. The Oncologist 2002;7(suppl 5):11-19.
14. Burris 3rd HA, Hanauske AR, Johnson RK et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 1992;84:1816-1820.
15. Bence AK, Mattingley CA, Desimone PA et al. Evaluation of topotecan cytotoxicity and topoisomerase I levels in nonsmall cell lung cancer cells. 93rd Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2002:1227a.
16. Hochster H, Liebes L, Speyer J et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994;12:553-559.
17. Hochster H, Wadler S, Runowicz C et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J Clin Oncol 1999;17:2553-2561.
18. Gore M, Rustin G, Schüller J et al. Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer. Br J Cancer 2001;84:1043-1046.
19. Brown 3rd JV, Peters 3rd WA, Rettenmaier MA et al. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Gynecol Oncol 2000;79:495-498.
20. Markman M, Kennedy A, Webster K et al. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol Oncol 2000;79:116-119.
21. Miller DS, Blessing JA, Lentz SS et al. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Society of Gynecologic Oncologists 33rd Annual Meeting, Nashville, TN, 2002:100a.
22. Herzog TJ, Rader JS, Gibb RK et al. Phase II study of three-day topotecan for recurrent primary peritoneal and epithelial ovarian cancer in platinum sensitive patients. Society of Gynecologic Oncologists 33rd Annual Meeting, Nashville, TN, 2002:86a.
23. Brown 3rd JV, Peters 3rd WA, Rettenmaier MA et al. Three consecutive day topotecan is an active regimen for recurrent epithelial ovarian cancer. Society of Gynecologic Oncologists 33rd Annual Meeting, Nashville, TN, 2002:58a.
24. Data on file. GlaxoSmithKline, Philadelphia, PA:2001.
25. McCabe FL, Johnson RK. Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan. Cancer Invest 1994;12:308-313.
26. Rose PG, Gordon NH, Fusco N et al. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. Gynecol Oncol 2000;78:228-234.
27. Haas NB, LaCreta FP, Walczak J et al. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 1994;54:1220-1226.
28. Homesley HD, Hall DJ, Martin DA et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 2001;83:394-399.
29. Morris RT, Munkarah A, Field J et al. Phase II trial of weekly topotecan in patients with potentially platinum sensitive relapsed ovarian and peritoneal cancer. Proc Am Soc Clin Oncol 2002;21:2512a.